These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7910836)

  • 21. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
    Leroux-Roels I; Koutsoukos M; Clement F; Steyaert S; Janssens M; Bourguignon P; Cohen K; Altfeld M; Vandepapelière P; Pedneault L; McNally L; Leroux-Roels G; Voss G
    Vaccine; 2010 Oct; 28(43):7016-24. PubMed ID: 20728522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
    Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
    J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.
    Moss RB; Wallace MR; Giermakowska WK; Webb E; Savary J; Chamberlin-Brandt C; Theofan G; Musil R; Richieri SP; Jensen FC; Carlo DJ
    J Infect Dis; 1999 Sep; 180(3):641-8. PubMed ID: 10438350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoproliferation in HIV-1-infected patients undergoing active HIV-1-specific immunotherapy.
    Trauger RJ; Giermakowska W; Wormsley S; Turner J; Jensen FC; Carlo DJ
    Clin Exp Immunol; 1995 Apr; 100(1):7-12. PubMed ID: 7697926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH; Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS
    J Infect Dis; 1996 Feb; 173(2):340-8. PubMed ID: 8568294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.
    Nayak BP; Sailaja G; Jabbar AM
    J Virol; 2003 Oct; 77(20):10850-61. PubMed ID: 14512535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice.
    Trabattoni D; Clivio A; Bray DH; Bhagat L; Beltrami S; Maffeis G; Cesana E; Lowry P; Lissoni F; Kandimalla ER; Sullivan T; Agrawal S; Bartholomew R; Clerici M
    Vaccine; 2006 Feb; 24(9):1470-7. PubMed ID: 16221513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
    Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.
    Fernandez-Cruz E; Moreno S; Navarro J; Clotet B; Bouza E; Carbone J; Peña JM; Pérez Molina J; Podzamczer D; Rubio R; Ocaña I; Pulido F; Viciana P; Maradona JA; Blazquez R; Barros C; Quereda C; Rodriguez-Sainz C; Gil J; Abad ML; Díaz L; Cantó C; Muñoz MA; Ferrer E; Jou A; Sirera G; Díaz M; Lopez F; Gatell JM; Gonzalez-Lahoz J;
    Vaccine; 2004 Aug; 22(23-24):2966-73. PubMed ID: 15297045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.
    Vijayan A; García-Arriaza J; Raman SC; Conesa JJ; Chichón FJ; Santiago C; Sorzano CÓ; Carrascosa JL; Esteban M
    PLoS One; 2015; 10(7):e0133595. PubMed ID: 26208356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the immune response and protective effects of rhesus macaques vaccinated with biodegradable nanoparticles carrying gp120 of human immunodeficiency virus.
    Himeno A; Akagi T; Uto T; Wang X; Baba M; Ibuki K; Matsuyama M; Horiike M; Igarashi T; Miura T; Akashi M
    Vaccine; 2010 Jul; 28(32):5377-85. PubMed ID: 20472029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
    Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
    Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.